Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vatiquinone · PTC-743, EPI-743

Small molecule · developed by PTC Therapeutics

Phase 3 Most advanced trial
PTCT Developer
4 Registered trials

What is Vatiquinone?

Vatiquinone (PTC743, EPI-743) is an oral solution agent studied in Friedreich ataxia and Leigh syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PTC-743, EPI-743
Drug type
Small molecule
Therapy area
Neurology
Developer
PTC Therapeutics (PTCT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
6O85FK9I0X

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05515536 Phase 3 Friedreich Ataxia Active not recruiting PTCT
NCT02352896 Phase 2 Leigh Syndrome Completed PTCT
NCT01728064 Phase 2 Friedreich's Ataxia Completed PTCT
NCT01721733 Phase 2 Leigh Syndrome Completed PTCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Friedreich AtaxiaFriedreich's AtaxiaLeigh Syndrome

More from PTC Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PTCT page.

Follow PTCT, the company behind Vatiquinone

See PTCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PTCT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.